We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The initial clinical outcomes of upadacitinib for RA ...
Baricitinib displayed long-term effectiveness and safety in pediatric patients with atopic dermatitis (AD), recent study data show. The phase 3 study included 467 patients between ages 2 and 17. At ...
A panel of outside experts to the U.S. Food and Drug Administration voted against backing the risk-benefit profile of AstraZeneca's breast cancer drug, the company said on Thursday.
UGN-102 achieved a 78% complete response rate at 3 months in the phase 3 ENVISION trial for recurrent low-grade NMIBC. The FDA's Oncologic Drugs Advisory Committee narrowly voted against the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results